Open AccessCharacterization of Humoral and Cellular Immune Responses Elicited by a Recombinant Adenovirus Serotype 26 HIV-1 Env Vaccine in Healthy Adults (IPCAVD 001)
Author(s) -
Dan H. Barouch,
Jinyan Liu,
Lauren Peter,
Peter Abbink,
M. Justin Iampietro,
Anthony P. Cheung,
Galit Alter,
Amy W. Chung,
Anne Sophie Dugast,
Nicole Frahm,
M. Juliana McElrath,
Holger Wenschuh,
Ulf Reimer,
Michael S. Seaman,
Maria Grazia Pau,
Mo Weijtens,
Jaap Goudsmit,
Stephen R. Walsh,
Raphael Dolin,
Lindsey R. Baden
Publication year - 2012
Publication title -
the journal of infectious diseases (online. university of chicago press)/the journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.69
H-Index - 252
eISSN - 1537-6613
pISSN - 0022-1899
DOI - 10.1093/infdis/jis671
Subject(s) - immunogenicity , immune system , immunology , biology , virology , cellular immunity , humoral immunity , antibody
Adenovirus serotype 26 (Ad26) has been developed as a novel candidate vaccine vector for human immunodeficiency virus type 1 (HIV-1) and other pathogens. The primary safety and immunogenicity data from the Integrated Preclinical/Clinical AIDS Vaccine Development Program (IPCAVD) 001 trial, the first-in-human evaluation of a prototype Ad26 vector-based vaccine expressing clade A HIV-1 Env (Ad26.ENVA.01), are reported concurrently with this article. Here, we characterize in greater detail the humoral and cellular immune responses elicited by Ad26.ENVA.01 in humans.